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Abstract
Background: Controlled trials have found therapeutic plasma exchange (TPE) and intravenous immunoglobulin
(IVIg) infusion therapy to be equally efficacious in treating Guillain-Barré syndrome (GBS). Due to increases in the
price of IVIg compared to human serum albumin (HSA), used as a replacement fluid in TPE, we examined direct
hospital-level expenditures for TPE and IVIg for meaningful cost-differences between these treatments.
Methods: Using financial data from our two institutions, hospital cost profiles for IVIg and 5% albumin were
established. Reimbursement amounts were obtained from publicly available Medicare data resources to determine
payment rates for TPE, non-tunneled central catheter line placement, and drug infusion therapy. A model was
developed which allows hospitals to input cost and reimbursement amounts for both IVIg and TPE with HSA that
results in real-time valuations of these interventions.
Results: The direct cost of five IVIg infusion sessions totaling 2.0 grams per kilogram (g/kg) body weight was
$10,329.85 compared to a series of five TPE procedures, which had direct costs of $4,638.16.
Conclusions: In GBS patients, direct costs of IVIg therapy are more than twice that of TPE. Given equivalent
efficacy and similar severity and frequencies of adverse events, TPE appears to be a less expensive first-line therapy
option for treatment of patients with GBS.
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Background
Guillain-Barré syndrome (GBS), the most common
cause of acute neuromuscular paralysis in the U.S. with
an incidence of 1 to 2 per 100,000, is an immune
mediated demyelinating polyneuropathy mainly affecting
motor and sensory peripheral nerves. Characterized by
paresthesias, weakness, and ascending paralysis in a dis-
tal to proximal pattern, GBS patients may also demon-
strate autonomic nerve dysfunction further complicating
their recovery. The majority of severely affected patients
require hospitalization, especially those with oropharyn-
geal and respiratory muscle involvement. Ventilator
support may be needed in 30% of all GBS patients [1].
Efficacy of therapeutic plasma exchange (TPE) has
been demonstrated in randomized trials comparing sup-
portive care or corticosteroid therapy in GBS patients.
TPE reduces ventilator support days and shortens time
to unaided walking resulting in earlier hospital discharge
[2]. Trials comparing TPE with intravenous immunoglo-
bulin (IVIg) have demonstrated equivalency of the two
in shortening time to unaided walking and reducing
length of ventilator support [3]. In a summary of five
trials with a combined enrollment of 582 patients, TPE
when compared to IVIg was found to be equivalent with
regard to improvement in disability grade with no signif-
icant differences in other outcome measures [4]. Based
on such data demonstrating equivalence of these two
treatment options, the American Academy of Neurology
has concluded that TPE and IVIg are equivalent and
recommended either for the treatment of non-ambula-
tory patients [5].
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ment of GBS, concern has arisen over whether the safety
profile of the two treatments is equivalent. The initial
trial comparing IVIg to TPE found a lower overall
adverse event rate with IVIg [6]. A subsequent larger
trial, however, found similar adverse event rates, with the
majority being transient and mild [3]. Subsequent meta-
analysis of available data found a relative risk of compli-
cations with IVIg compared to TPE of 0.84 but the 95%
confidence interval (0.54 to 1.30) crossed 1, indicating
equivalency [7]. These findings suggest that not only are
the two treatments equivalent with regard to patient
response but also with regard to potential risks.
Many physicians, however, prefer IVIg for the treat-
ment of patients with severe GBS. This preference may
be due partly to the 1997 Plasma Exchange/Sandoglobu-
lin Guillain-Barré Syndrome Trial that reported, “On
grounds of equal therapeutic benefit, greater conveni-
ence and similar overall cost, IVIg may be preferable to
TPE for treatment of adult patients with Guillain-Barré
syndrome...provided there are no contraindications to
IVIg” [3]. At the time of this trial, the average price of
IVIg in the U.S. was approximately $30 per gram [8]. In
the decade following this study, prices for IVIg increased
to >$60 per gram for liquid formulations and >$50 per
gram for the powder formulation [8]. Additionally, in
2005, manufacturers instituted allocation programs due
to supply shortages that restricted IVIg availability.
Some hospitals have had to establish triage plans allo-
cating IVIg use only for approved indications whereas
others have required consideration of alternate treat-
ments, like TPE, for patients with neurologic disorders
[9]. Several factors contribute to IVIg shortages includ-
ing consolidation in the blood product industry, the
switch from the manufacturing of powder to liquid pre-
parations, production cuts by some manufacturers and a
lag time in production when firms change manufactur-
ing processes [10]. Additional supply pressures result
from steadily increasing clinical demands for the off-
label use of IVIg at a rate of 5-10% annually [11]. Dur-
ing these periods, IVIg prices have risen more than 20%
and as of April 2010, the average price for liquid formu-
lations of IVIg had increased to $70.22 per gm.
During this same time, human serum albumin (HSA)
prices averaged $30 for a 250 ml bottle. HSA prices
reached a low in 2004-2005 and were less than one-half
the1999 price in 2007. As of April 2010, the price of a
250 ml bottle of 5% HSA was $34.06.
Based on the above considerations, we re-examined
the assumption of cost parity between a standard course
of IVIg and a series of five TPEs by performing a cost-
minimization analysis to determine whether meaningful
differences in the direct cost currently exist between
these two therapeutic options.
Methods
A cost-minimization analysis comparing a typical course
of five TPEs against five IVIg infusions was performed.
The model was developed from the study data included
in Tables 1 and 2 and was created in a spreadsheet
(Excel 2003, Microsoft Corporation, Redmond WA) and
is available as additional file 1 to this manuscript. The
model provides hospitals an opportunity to include their
own direct costs and reimbursement amounts from any
specific payer to arrive at real-time values.
Assumptions
Basic assumptions about each treatment regimen are
given in Table 3. With regard to the number of TPE
procedures, in patients not requiring respiratory sup-
port, a course of two TPEs has been compared to four
with the later being superior in multiple outcome mea-
sures. In more severely affected individuals, a course of
four TPEs was compared to six and both were found to
be equivalent with the exception of a higher frequency
of hypotension with six TPEs [12]. Based upon these
findings, recommendations in published guidelines [13],
and to maximize the costs of TPE, a course of five TPEs
was selected. We conservatively selected the highest
plasma exchange volume for this clinical indication
based upon the medical literature [13]. We assumed an
average 70 kg adult and an 80:20 replacement fluid mix
of 5% HSA and normal saline, resulting in 14,000 ml of
HSA to complete all five TPE procedures. Alternate
replacement colloids to 5% HSA, such as hydroxyethyl
starch solutions, can be used and are less expensive
than 5% HSA. In addition, a lower percentage of HSA,
such as 60:40 or 50:50 HSA to saline could also be used
Table 1 Direct hospital costs of a five-treatment inpatient
course of intravenous immunoglobulin (IVIg)
Resource Cost *
IVIg, 0.4 g/kg (70 kg patient) × 5 infusions @ $70.22/g
a $9,830.80
Direct RN labor cost (73 min × $0.79/min)
b cost ×
5 infusions
$474.00
IVIg infusion supplies × 5 infusions
c $25.05
TOTAL COST $10,325.05
a IVIg hospital cost $70.22 shown above is based on hospital contracted prices
paid to manufacturers. Starting in Q1-2011 Medicare OPPS (outpatient
prospective payment system) IVIg reimbursement is $73.30/gram based on
average of five IVIg brands. Medicare payment rates for Q1-2011 are based on
106% of third quarter 2010 manufacturer’s reported average sales price, which
serves as a proxy for hospital acquisition cost, distributor mark-up and direct
overhead including storage, preparation and disposal costs).
b Center for Medicare and Medicaid Services (CMS). CY 2010 Labor file. RUC
source for CPT 96365 and 96366. Assumes an average two-hour infusion (one
unit each of CPT 96365 + CPT 96366), which utilizes 59 minutes and 14
minutes (total 73 minutes) of nurse clinical labor time. This value understates
typical labor costs for a PE nurse operator, which is better approximated by
the RUC value of $0.79/minute applied for therapeutic intravenous infusions;
we used that higher labor rate in our cost model.
c CMS. CY 2010 Supplies file. RUC source for CPT 96365 and 96366.
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these alternate replacement fluids and fluid mixtures are
associated with a higher frequency of reactions and are
not consistent with recommendations for replacement
fluids in published guidelines [13]. In addition, utilizing
this replacement fluid mixture maximize the costs asso-
ciated with TPE and represents a worst-case scenario.
Central venous catheter placement for venous access in
GBS patients treated with PE is not always necessary
but we conservatively assumed that all patients would
require this. We assumed that serious adverse events
(AEs) attributable to TPE or IVIg occur infrequently at
similar rates and that associated costs would not directly
affect this analysis. Finally, we also assumed that the
length of hospitalization would be equivalent between
the two therapies given the equivalent time to response
between the two [3,4]. Both therapies can be performed
as an outpatient once the patient has responded.
Sources of direct costs
Direct labor costs were obtained from the Center for
Medicare and Medicaid Services (CMS) Clinical Practice
Expense Panel (CPEP) clinical labor database for plasma
exchange and intravenous infusion [14]. Supply costs for
a TPE procedure, totaling just over $210, were identified
in the CPEP supply database. The administration set and
other supplies for an IVIg infusion cost less than $6 [14].
The direct hospital-level costs for HSA and IVIg are
n o tp u b l i s h e da sp r i c e sa n da r ed r i v e nb yh o s p i t a lc o n -
tracts. CMS does, however, publish drug pricing files
based on manufacturer reported average sales prices
(ASP). Effective January 1, 2011 the agency uses these to
develop reimbursement amounts by adding 6% to the
manufacturer reported ASP for physician offices and the
same 6% under outpatient prospective payment system
(OPPS) for hospital outpatient reimbursement. Values
used for reimbursement in this cost minimization analy-
sis represent 106% of third quarter 2010 manufacturers’
U.S. average sales prices for IVIg. For data used in the
Budget Impact Model, we used the most current reim-
bursement rate for IVIg reimbursement from Medicare;
the IVIg reimbursement of $73.226/gram equates with
first quarter 2011 Medicare OPPS (outpatient prospec-
tive payment system) payment rate averaged across five
liquid IVIg products (J1459, J1561, J1568, J1569, J1572)
(Medicare reimbursement rates are for third quarter
2011 based on 106% of third quarter 2010 manufac-
turer’sr e p o r t e da v e r a g es a l e sp r i c e ,w h i c hs e r v e sa sa
proxy for hospital acquisition cost, distributor mark-up
and direct overhead including storage, preparation and
disposal costs) [15].
HSA, however, is still reimbursed under the AWP
(Average Wholesale Price) formula. These values serve
as proxies for the hospital reimbursement and include
acquisition cost, distributor mark-up, and direct over-
head related to product storage, preparation and dispo-
sal [15]. For hospital drug costs we used average prices
paid by the two hospitals, based on contracts. The aver-
age hospital cost from two hospitals for IVIg was $
70.22/gram and the average cost for 5% HSA was
$35.35/250 ml bottle.
The surgeon’s fee for placement of a central venous
catheter is not a hospital cost and is not included in the
Table 2 Direct hospital costs of a five-treatment inpatient
course of therapeutic plasma exchange (TPE)
Resource Cost *
Tubing set and all other supplies ($210.08)
a × 5 procedures $1,050.40
Direct RN labor cost (120 min × $0.79/min)
b cost ×
5 procedures
$474.00
Insert central venous catheter (incl. catheter kit, supplies,
x-rays); hospital costs
c
$750.81
5% albumin × 5 procedures
d $1,990.00
TPE equipment amortization
e × 5 procedures
($52.59/procedure)
$262.95
Service contract amortization
f × 5 procedures $110
TOTAL COST $4,638.16
a CMS. CY 2010 Supplies file. PEAC (Practice Expense Advisory Committee)
source for CPT 36514. March 2004 update.
b CMS. CY 2010 Labor file. PEAC source for CPT 36514. March 2004 update.
For PE (CPT 36514), the CMS Labor file cites a labor cost of $0.42/minute,
based on an RN/LVN operator. This value understates typical labor costs for a
PE nurse operator, which is better approximated by the RUC value of $0.79/
minute applied for therapeutic intravenous infusions; we used that higher
labor rate in our cost model.
c CMS. CY 2010 payment amount for APC 0621. (Medicare-reported true
median hospital cost for insertion of non-tunneled central venous catheter or
PICC line; paid under APC 0621; surgeon’s fee is separately paid.).
d 40 ml/kg 5% albumin (50 ml/kg total fluid volume replacement with 80%
albumin:20% saline) × 70 kg patient × 5 procedures = 14,000 ml = 56 vials of
250 ml 5% albumin × $35.53/vial = $1,990 Albumin cost of $35.53 per vial
represents the January 2011 provider contracted acquisition cost. Medicare
payment rate is set at 95% of AWP for albumin, which serves as a proxy for
hospital acquisition cost, distributor mark-up and direct overhead including
storage, preparation and disposal costs.
e CMS. CPEP equipment file, March 2004 update (most recent data). Includes
cell separator system, blood warmer and medical recliner chair, with useful
lives of 6, 7 and 10 years (200 procedures per year) and costs of $59,320,
$3,840 and $829, respectively.
f $4,450 annually per cell separator system (CaridianBCT device); assumes 200
procedures per year per device.
Table 3 Basic assumptions applied regarding therapeutic
plasma exchange and intravenous immunoglobulin
infusion treatment regimens in study
Therapeutic Plasma Exchange (TPE) Intravenous
immunoglobulin infusion
(IVIg)
￿ Five plasma exchanges totaling 250 ml/
kg total plasma volume replacement
￿ 80% volume replacement with 5%
human albumin; 20% volume with saline
or other crystalloid
￿ 70 kg mean body weight
￿ Non-tunneled subclavian or intrajugular
catheter placed in all patients
￿ 5 IVIg infusions totaling
2.0 g/kg
￿ 70 kg mean body weight
￿ Infusions started and
monitored by a nurse
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global direct cost comparison, the average Medicare sur-
geon payment for non-tunneled central venous line pla-
cement is $130. Physician medical management and
oversight fees for either TPE or IVIg infusions were not
included in the analysis.
Results
Direct hospital costs related to IVIg and TPE treatment
are provided in Tables 1 and 2. The estimated direct
cost for IVIg infusion therapy to treat a 70 kg adult is
$10,305 (Table 1). This is approximately 159% more
than the $3,980 direct cost of a course of TPE for the
same 70 kg adult (Table 2).
Whereas IVIg prices have risen in recent years, in
contrast, HSA prices have been more volatile. At its cost
peak in 1999-2000, the price for HSA at our two institu-
t i o n sa v e r a g e db e t w e e n$ 5 5a n d$ 5 8p e r2 5 0m lb o t t l e .
As HSA represents the single largest TPE cost element,
we calculated a 50% and 100% increase in the current
cost of $36.48 per 250 ml bottle of HSA to determine
how this might affect the comparative cost outcome. As
of January 1, 2011, CMS reimburses $67.07 per 250 ml
bottle based on the AWP formula. Hospital costs for
HSA are significantly lower than this amount, $35.53 for
250 ml. The price of HSA would have to increase
approximately five fold for TPE to match the cost of
IVIg drug costs.
Discussion
Given the higher cost of IVIg relative to TPE, a reassess-
ment of their clinical benefits and associated AEs is rele-
vant. The Guillain-Barré Syndrome Study Group first
established the efficacy of TPE when 245 patients were
randomized to receive five to six one plasma volume
exchanges over 14 days or “best supportive care” at 21
North American treatment sites [16]. In this study, the
TPE group experienced a shorter median time to
improve one grade (19 vs. 40 days; p < 0.001), better
percentage of subjects who had improved one grade at 4
weeks (59% vs. 39%, p < 0.01), shorter time to walk
unassisted (53 vs. 85 days; p < 0.001) and shorter mean
time on ventilator support (24 vs. 48 days, p < 0.01).
TPE and supportive care demonstrated no difference in
complication frequency [16]. A Cochrane Database
review of six clinical trials (649 patients) confirmed that
TPE is superior to supportive care across multiple func-
tional outcome measures [17]. TPE was associated with
fewer severe sequelae after one year, fewer infectious
events and fewer cardiac arrhythmias than supportive
care. The reviewers concluded that TPE is “the first and
only treatment that has been proven to be superior to
supportive treatment alone,” and should be regarded as
the standard against which new treatments should be
judged [17].
Consequently, TPE has served as the standard treat-
ment arm for two large randomized trials examining
IVIg use in patients with severe GBS. In 1992, the
Dutch Guillain-Barré Study Group randomized 147
patients to five to six TPEs or five daily IVIg infusions
of 0.4 grams/kg [6]. The use of IVIg was associated with
a shorter median time to improve one grade and a sig-
nificantly higher percentage of subjects who improved
one or more grades at four weeks. At three-month
examination, however, no significant difference in this
primary outcome was seen [6]. Of note in this study
those treated with TPE did no better than patients in
the Guillain-Barré Syndrome Study Group trial who
received supportive care. It was subsequently identified
that the Dutch Guillain-Barré Study Group study did
not appropriately compare the two therapies [18,19].
The definition of functional grade 3 as “able to walk
≥10 m with a walker or support” resulted in the inclu-
sion of patients in the study who would have been clas-
sified as functional grade 2 excluded by the Guillain-
Barré Syndrome Study Group. The enrollment of less
severely affected GBS patients may have masked the
effectiveness of TPE. Of greater concern was inadequate
matching in the study treatment arms. The TPE group
was older and 41% of subjects had diminished com-
pound muscle potentials at baseline. In comparison, the
IVIg group was younger with diminished compound
muscle potentials in only 27% of patients. Age and
diminished compound muscle potentials are the two
most reliable negative prognostic factors for response to
TPE in GBS. Similar problems with equivalency of the
TPE and IVIg groups were also seen in a more recent
study by Alshekhlee et al where patients receiving TPE
were older with higher complication rates and, not sur-
prisingly, higher mortality rates [20].
The second larger trial by the Plasma Exchange/San-
doglobulin Guillain-Barré Syndrome Trial Group found
equivalency between IVIg and TPE in patients across
multiple disability parameters, with equivalent low rates
of treatment complications and numbers of deaths [3].
While TPE could, in theory, increase the risk of infec-
tion and hemorrhage through the removal of immuno-
globulins and clotting factors, neither AEs occurred
more frequently in the TPE group compared to the IVIg
group in this trial [3] or in trials of TPE tested against
supportive care.
Table 4 shows AEs associated with TPE and IVIg
treatment. The side-effect profiles are similar with
regard to severity and frequency of mild and severe
reactions. The profiles differ with regard to types of
reactions and their underlying pathophysiology.
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with TPE have been reported to occur in 4.75% to 36%
of procedures [21-23]. The vast majority of reactions are
mild, easily treated, and self-limited [21-23]. Severe reac-
tions, defined as those with the potential to be life
threatening, have been reported to occur in 0.12% of
TPEs [21]. Couriel and Weinstein observed a higher
incidence of severe reactions, 6.15%, with all being
related to central line placement complications where
only 23% of the patients were treated via peripheral access
[22]. In contrast, Basic-Jukic et al noted a lower reaction
rate in a study where 72% of the TPE procedures were
performed with peripheral vascular access [21]. Thus with
TPE the frequency of reactions directly attributable to the
procedure performed via peripheral access is less than
those due to central line placement [22]. While it is fre-
quently assumed that all patients undergoing TPE for neu-
rologic diseases require central line placement, studies
demonstrating that a majority (72 to 96%) of patients can
satisfactorily undergo TPE using peripheral vascular access
suggest otherwise [22,24].
Frequency of adverse effects of IVIg has been reported
to occur in 11 to 81% of patients receiving infusions
with more recent studies demonstrating reaction rates
of 36% to 42% [25,26]. As with TPE, the majority are
mild, easily treated, and self-limited. The frequency of
severe, life threatening, reactions is rare [25-28].
Reducing unnecessary costs is critical to addressing
the growing lack of affordability of health care, now
reflected in the fact that 15% of Americans do not have
health insurance [29]. Hospitals are motivated to find
opportunities to reduce costs without compromising
patient outcome, particularly in the inpatient setting
where prospective payment arrangements with public-
and private-sector insurers reward cost containment.
Reimbursement in most instances is defined prospec-
tively and remains fixed regardless of the actual costs of
care for an individual patient. Medicare, for example,
pays most hospitals a fixed payment amount based on
the Diagnosis Related Group (DRG) to which the stay is
assigned. Most private insurers pay a fixed per diem rate
that is typically independent of how much is spent on
procedures, drugs, supply items and other resources.
Since the Plasma Exchange/Sandoglobulin Guillain-
B a r r éS y n d r o m et r i a l ,t h ep r esumption of similar costs
may have influenced neurologists to use IVIg as a first-
line for treatment of GBS rather than TPE. Similarly,
the use of IVIg rather than TPE in the management of
other neurological conditions (Table 5), including
chronic inflammatory demyelinating polyneuropathy and
myasthenia gravis may also be affected by this perspec-
tive [30-33].
The average price for IVIg since the Plasma Exchange/
Sandoglobulin Guillain-Barré Syndrome trial has more
than doubled from approximately $30 per gram to
$70.22 as of April 6, 2010 [3]. While the cost of HSA
used for volume replacement in TPE is not inconsider-
able, it is dwarfed by a 2.2 times higher average IVIg
price. Use of less than an average of 2.8 liters of HSA
per procedure due to smaller patient plasma volumes
further widens this HSA-IVIg cost gap. Other resources
required to perform a TPE procedure (e.g. the nurse
Table 4 Side-effect profiles of intravenous
immunoglobulin infusion and therapeutic plasma
exchange
Intravenous Immunoglobulin
Infusion [25-28]
Therapeutic Plasma
Exchange [21-23]
Mild (common) Mild (common)
Fever Fever
Facial flushing Paresthesias due to
hypocalcemia
Malaise Hematoma at site of vascular
access
Headache Bleeding at site of vascular
access
Chills Muscle cramping due to
hypocalcemia
Myalgia Nausea
Fatigue Vomiting
Dyspnea Pallor
Back Pain Diaphoresis
Abdominal pain Hypotension
Nausea Tachycardia
Vomiting Urticaria
Diarrhea Pruritis
Hypotension Hypofibrinogenemia
Tachycardia
Urticaria
Pruritis
Pseudohyponatremia
Severe (uncommon) Severe (uncommon)
Anaphylaxis Anaphylaxis
Acute renal failure Air embolism
Thromboembolic events Arrhythmia
Stroke Hemolysis
Myocardial infarction Thrombocytopenia
Deep venous thrombosis Transfusion Related Acute Lung
Injury
Aseptic meningitis Pneumothorax due to central
line
Progressive neurodegeneration Hemothorax due to central line
Serum sickness Tetany
Hemolysis
Neutropenia
Transfusion Related Acute Lung Injury
Uveitis
Leukocytoclastic vasculitis
Erythema multiforme
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and amortization of the blood processing device) are
less than 25% of the cost of a series of five IVIg infu-
sions used to treat a 70 kg adult patient.
Little has been published comparing the costs of IVIg
and TPE for GBS. Early studies found TPE to be cost-
saving [34]. However, in 1999; Canadian investigators
published a cost minimization analysis that may have
overstated costs for IVIg and albumin. While the Cana-
dian group found that TPE was more cost effective than
IVIg (TPE $6,204/patient versus IVIg $10,165/patient),
they may have inadvertently incorporated published
“list” prices for IVIg products, producing an averaged
cost estimate roughly two-fold higher than the actual U.
S. market price for IVIg at that time [35]. An assumed
average cost of $90 per 250 ml bottle of HSA was again
dramatically higher than the U.S. hospital-level price of
HSA at any time over the last decade. This group also
applied an hourly nurse labor cost ($15.25) that was
substantially lower than 1999 prevailing U.S. hourly
wage ($21.38) for registered nurses [36]. Such cost
assumptions, coupled with ane s c a l a t i o ni np r i c e so f
IVIg products over the last several years, supports a re-
examination and cost analysis of IVIg and TPE in GBS.
Another notable exception to the lack of economic ana-
l y s e si st h ew o r kb yT s a i ,W a n ga n dL i u[ 3 7 ] .T h e
authors retrospectively examined 24 patients with GBS
who were admitted to the Taipei Veterans General Hos-
pital, 10 of whom were treated with TPE, seven with
IVIg, and seven who received supportive treatment and
were treated in the study as a control group. They con-
cluded that despite the significantly lower cost for TPE,
total costs were lower in the IVIg group [37]. In a
response to the study, Buenz raised several critical ques-
tions [38]. While the age difference between the two
groups was not statistically significant, Buenz suggested
that the difference between an 83-year-old and a 45
year-old-patient (statistically equally as probable accord-
ing to the data presented where the 95% confidence
interval for the age difference is -5.12 to 38.5 years) is
clinically significant with regard to GBS prognosis,
regardless of the therapeutic intervention [38]. Second,
the severity of disease and co-morbidities are not ade-
quately described. Since patients receiving IVIg in Taipei
must personally pay out-of-pocket expenses for their
therapy it is reasonable to question whether wealthier
and potentially younger patients with less co-morbidity
seen earlier in their disease course may comprise and
bias the cohort examined. Finally, the authors state that
the incidence of complications is the same while the
cost for treatment is higher for the TPE group. One
patient in each group had pneumonia. Since there is no
reason to assume that the cost of treating pneumonia
would be higher in one group or the other, it is assumed
t h a tt h es o l ed i f f e r e n c ei nt h ec o s to fc o m p l i c a t i o n si s
from a septic patient. The assertion that TPE is more
expensive than IVIg is based on this single patient with
sepsis where the nature and source of the infection is
unreported. While the study provides an important con-
tribution to the literature on TPE and IVIg, it raises
concerns that require additional research [38].
In a more recent detailed study of the economic cost
of GBS in the U.S., the lifetime health burden in mone-
tary terms for 5,500 GBS patients was examined [39].
Such a study provides information to assess cost-effec-
tiveness of health measures that affect GBS. The
Table 5 Neurologic diseases treated with both intravenous immunoglobulin infusion and therapeutic plasma
exchange
Neurologic Disease Role of intravenous
immunoglobulin infusion in
treatment [33]
Role of therapeutic plasma exchange in treatment [13]
Acute inflammatory demyelinating
polyneuropathy (AIDP, Guillain-Barré
syndrome)
Definite First line therapy with a strong recommendation and high-quality
evidence. (Category I, Recommendation grade 1A)
Chronic inflammatory demyelinating
polyneuropathy (CIDP)
Definite First line therapy with a strong recommendation and moderate
quality evidence. (Category I, Recommendation grade 1B)
Lambert-Eaton myasthenic syndrome
(LEMS)
Probable Second line therapy with a weak recommendation and low quality
or very low quality evidence. (Category II, Recommendation grade
2C)
IgM anti-myelin associated glycoprotein
paraprotein associated peripheral
neuropathy
Probable First line therapy with a strong recommendation and low quality or
very low quality evidence. (Category I, Recommendation grade 1C)
Myasthenia gravis (MG) Probable First line therapy with a strong recommendation and high-quality
evidence. (Category I, Recommendation grade 1A)
Multiple sclerosis (MS) Possible Second line therapy with a strong recommendation and moderate
quality evidence. (Category II, Recommendation grade 1B)
Acute disseminated encephalomyelitis
(ADEM)
Possible Second line therapy with a weak recommendation and moderate
quality evidence. (Category II, Recommendation grade 2C)
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$1.6 to 1.9 billion) including $200 million (14%) in
direct medical costs and $1.5 billion (86%) in indirect
costs. In our work, we focused solely on assessing the
savings in drug costs. At $5,350.00 per course of five
treatments multiplied by the number of treatments per
year times the number of GBS patients treated at a
given hospital, a significant budget impact on pharmacy
costs could quickly accrue.
We intentionally did not consider “indirect cost” that
hospitals may assign to the physical floor space required
to perform a TPE procedure in our analysis. Space
valuation is variable between institutions, reflecting dif-
ferences in revenue and accounting practices. This
valuation would be small on a per-procedure basis and
therefore would not significantly affect this analysis. In
addition, assignment of an indirect cost for physical
space is financially relevant only if the treatment of this
patient population requires addition of an apheresis
medicine treatment unit. If existing apheresis medicine
service capacity can absorb those procedures, it is diffi-
cult to argue that the hospital has incurred a new “cost.”
Our study is limited in three significant ways. First,
while AEs attributable to TPE and IVIg occurred with
similar frequencies in the 1997 Plasma Exchange/Sando-
globulin Guillain-Barré Syndrome Trial, the nature of
those events was different between the two groups. It is
therefore possible that the overall costs of treating these
AEs will also be dissimilar. This, however, may be of no
importance since the complications for both treatments
are typically mild and self-limited requiring minimal
intervention. Second, we did not consider the influence
of either abbreviated TPE or IVIg treatment courses on
overall costs. In the Plasma Exchange/Sandoglobulin
Guillain-Barré Syndrome Trial, less than 75% of the
planned intervention was given to 13.8% of patients in
the TPE group versus just 2.3% in the IVIg group. All
subjects were included in the outcomes analysis. In
addition, alternate replacement fluids and/or a lower
percentage of HSA in the replacement fluid could be
used, though this is not consistent with published guide-
lines. If similar under-dosing rates or use of alternate
replacement fluids occur in current practice, this would
result in further reductions of the average cost of TPE.
Finally, our study examines only the direct costs of TPE
and IVIg, not the total costs. In order to determine total
costs it would be necessary to have data on the types
and frequency of adverse effects of the two treatments
as well the costs associated with treating these complica-
tions. Contemporary data is not available.
Conclusions
By treating GBS patients with a course of five TPE treat-
ments instead of five IVIg infusions, U.S. hospitals can
expect to realize a cost savings of more than $5,680.00.
For a given hospital, the magnitude of this cost advan-
tage will be only marginally affected by its average IVIg
and albumin acquisition costs and local nursing wage
rates. Considering the high cost of IVIg as a mainte-
nance therapy, especially for other conditions like
chronic inflammatory demyelinating polyneuropathy and
myasthenia gravis, institutions may realize significant
savings. Based not only on its efficacy and safety profiles
but on its financial considerations as well, TPE should
be strongly viewed as first line therapy in the treatment
of GBS patients.
Additional material
Additional file 1: The additional data file consists of a spreadsheet
(Excel 2003, Microsoft Corporation, Redmond WA) that contains the
model used in this manuscript to perform the cost minimization
analysis. Individual institutions can input their own direct costs and
reimbursement amounts from any specific payer and perform the
analysis reported in this study in real-time.
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